First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) kinase inhibitors are crucial in cancer therapy, but resistance often emerges.
• Nuclear factor kappa B (NF-κB) activation is a key survival mechanism driving resistance to EGFR inhibitors in cancers like nonsmall cell lung cancer.
• Targeting NF-κB alongside EGFR offers a potential strategy to overcome therapeutic resistance.

Purpose of the Study:

• To develop novel dual inhibitors targeting both EGFR kinase and NF-κB activity.
• To optimize compounds for potent inhibition of both pathways and evaluate their efficacy in preclinical cancer models.

Main Methods:

• Design and synthesis of thiourea quinazoline derivatives.
• NF-κB reporter gene assays to identify hit compounds.
• In vitro and in vivo efficacy studies in EGFR-overexpressing tumor cell lines and xenograft models.
• Molecular mechanism investigation of NF-κB suppression.

Main Results:

• Compound 9b demonstrated potent dual inhibition with IC50 values of 60 nM for EGFR kinase and 0.3 μM for NF-κB.
• Dual inhibitors exhibited superior potency in inhibiting cell growth compared to gefitinib in vitro and in vivo.
• No signs of toxicity were observed with the dual inhibitors.
• Mechanism revealed depletion of CREB-binding protein from the NF-κB complex.

Conclusions:

• Novel thiourea quinazoline derivatives act as effective dual inhibitors of EGFR kinase and NF-κB.
• These dual inhibitors represent a promising therapeutic strategy for overcoming EGFR inhibitor resistance in cancer.
• The compounds demonstrate potent antitumor activity and a favorable safety profile.